Report Highlights
- The global kinase inhibitors market reached $28.1 billion in 2010 and nearly $29.1 billion in 2011. The market is expected to reach $40.2 billion by 2016, a compound annual growth rate (CAGR) of 6.7%.
- The emerging markets segment for kinase inhibitors reached $2.9 billion in 2010 and $4.1 billion in 2011. The market is expected to reach $8.4 billion by 2016, a CAGR of 15.2%.
- The emerging markets segment for antibody kinase inhibitors reached $1.8 billion in 2010 and $2.1 billion in 2011. The market is expected to reach $4.3 billion by 2016, a CAGR of 15.2%.
INTRODUCTION
STUDY OBJECTIVES
BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for kinase inhibitors. The key objective is to present a comprehensive analysis and the future direction of kinase inhibitors to provide an important tool for the usage of these types of enzyme inhibitors.
This report explores present and future strategies within the kinase inhibitors market, which includes tyrosine inhibitors, multi-target kinase inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase inhibitors. The direction of the market, its setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of enzyme inhibitors are also examined in the report.
A detailed analysis of the kinase inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2011 through 2016.
Applications for kinase inhibitors are also discussed separately in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and a summary of patents awarded in each category.
REASONS FOR DOING THIS STUDY
Extensive research in the field of kinase inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of kinase inhibitors in their productions and processes. This has led to the steady market for them.
R&D spending along with increasing competition, patent expiries and new technologies are directing kinase inhibitors to new directions. The new advancements, new product launches and the changing lifestyle have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/ technology in light of the new technologies, growing competition and changing customer needs.
INTENDED AUDIENCE
This study contributes to the areas of market growth in kinase inhibitor manufacture and use. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.
SCOPE OF THE STUDY
The scope of this study encompasses kinase inhibitors in pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand and others countries.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
INFORMATION SOURCES
Many companies active in the kinase inhibitor industry were surveyed to obtain data for this study. Included were manufacturers and end users of kinase inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were conducted. In addition, data were compiled from current financial, trade and government sources.
BCC ONLINE SERVICES
Now you can obtain the important, hard-to-find information you need on the World Wide Web. By directing your browser to BCC Research’s new home page, you will be able to do the following:
- Examine BCC’s complete catalog of technology market research reports by tables of content, and order reports directly from BCC Research.
- Subscribe to any of its more than 20 monthly technology/marketing newsletters.
- Read announcements of upcoming reports and newly launched newsletters.
- Register for BCC’s well-known conferences.
- Request additional information about any BCC product.
- Take advantage of special offers.
To reach this important new information resource, go to www.bccresearch.com.
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
Related Reports
Kinase Inhibitors: Global Markets
The global kinase inhibitors market reached $28.1 billion in 2010 and nearly $29.1 billion in 2011. The market is expected to reach $40.2 billion by 2016, a compound annual growth rate (CAGR) of 6.7%.
Global Markets for Enzyme Inhibitors
The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.
Liver Disease Treatments: The Global Market
In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain stagnant at $12.4 billion. Estimated sales in 2011 a projected $12 billion (excluding protease inhibitors). The market is expected to rise at a CAGR of 3.3% and reach nearly $14.2 billion by 2016.
Enzymes in Industrial Applications: Global Markets
The global market for industrial enzymes is estimated at $3.3 billion in 2010. This market is expected to reach $4.4 billion by 2015, a compound annual growth rate (CAGR) of 6% over the 5-year forecast period.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Global Biochip Markets: Microarrays and Lab-on-a-Chip
The global market for biochip was valued at $16.1 billion in 2024 and is estimated to reach $27.8 billion by 2029, at a compound annual growth rate (CAGR) of 11.6% from 2024 through 2029.
Global Cell Line and Membrane Market
The global market for cell lines and membranes was valued at $5.7 billion in 2024 and is estimated to increase from $6.3 billion in 2025 to reach $11.4 billion by 2030, at a compound annual growth rate (CAGR) of 12.5% from 2025 through 2030.
Human Microbiome-based Drugs and Diagnostics: Global Markets
The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.
Global Microbiome Sequencing Market
The global microbiome sequencing market is expected to grow from $1.5 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.3% during the forecast period of 2024 to 2029.
Proteomics: Technologies and Global Markets
The global market for proteomic technologies was valued at $27.6 billion in 2024. It is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030.
Top Trending Reports
Next-Generation Advanced Batteries: Global Markets
The global market for next-generation advanced batteries is estimated to grow from $1.5 billion in 2024 to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 28.5% from 2024 through 2029.
Global Pharmaceutical Drugs Industry: Competitive Landscape 2023
This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.
Biologic Therapeutic Drugs: Technologies and Global Markets
The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.
Global Markets and Manufacturing Technologies for Protein Drugs
The global protein drugs market is expected to grow from $441.7 billion in 2024 and is projected to reach $655.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.
Global Markets for Emerging Medical Device Technologies
The global market for emerging medical devices is estimated to increase from $136.6 billion in 2024 to reach $223.9 billion by 2029, at a compound annual growth rate (CAGR) of 10.4% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More